

11<sup>th</sup> April 2018

To,

**1. Gilead Sciences, Inc.**

333 Lakeside Drive, Foster City  
California 94404, USA

**2. Medicines Patent Pool**

Chemin Louis-Dunant 17  
1202 Geneva, Switzerland

**Sub:** Termination of Tenofovir Disoproxil Fumarate (TDF), elvitegravir ("EVG"), cobicistat ("COBI"), Bictegravir ("BIC")

**Ref:** License Agreement dated 9<sup>th</sup> April 2018, executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Zhejiang Langhua Pharmaceutical Co.,Ltd.

Dear Sir/Madam,

In accordance with section 10.5 of the above License Agreement, Zhejiang Langhua Pharmaceutical Co.,Ltd hereby provides notice of termination of the license for Tenofovir Disoproxil Fumarate (TDF), elvitegravir ("EVG"), cobicistat ("COBI"), Bictegravir ("BIC")effective immediately.

We look forward to a fruitful and collaborative relationship with Gilead Science and the Medicines Patent Pool.

Yours Sincerely,



Zhejiang Langhua Pharmaceutical Co.,Ltd